HomeCompareCRHCF vs ABBV

CRHCF vs ABBV: Dividend Comparison 2026

CRHCF yields 2.39% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 CRHCF wins by $1.35M in total portfolio value· pulled ahead in Year 5
10 years
CRHCF
CRHCF
● Live price
2.39%
Share price
$53.56
Annual div
$1.28
5Y div CAGR
70.8%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$1.46M
Annual income
$1,047,804.46
Full CRHCF calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — CRHCF vs ABBV

📍 CRHCF pulled ahead of the other in Year 5

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCRHCFABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CRHCF + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CRHCF pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CRHCF
Annual income on $10K today (after 15% tax)
$203.13/yr
After 10yr DRIP, annual income (after tax)
$890,633.79/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, CRHCF beats the other by $869,577.79/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CRHCF + ABBV for your $10,000?

CRHCF: 50%ABBV: 50%
100% ABBV50/50100% CRHCF
Portfolio after 10yr
$779.2K
Annual income
$536,288.11/yr
Blended yield
68.83%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

CRHCF
Analyst Ratings
7
Buy
4
Hold
1
Sell
Consensus: Buy
Altman Z
3.0
Piotroski
7/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CRHCF buys
0
ABBV buys
0
No recent congressional trades found for CRHCF or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCRHCFABBV
Forward yield2.39%3.06%
Annual dividend / share$1.28$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR70.8%40.6%
Portfolio after 10y$1.46M$102.3K
Annual income after 10y$1,047,804.46$24,771.77
Total dividends collected$1.40M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusBuyBuy

Year-by-year: CRHCF vs ABBV ($10,000, DRIP)

YearCRHCF PortfolioCRHCF Income/yrABBV PortfolioABBV Income/yrGap
1$11,108$408.17$11,550$430.00$442.00ABBV
2$12,609$723.75$13,472$627.96$863.00ABBV
3$14,804$1,311.43$15,906$926.08$1.1KABBV
4$18,297$2,457.65$19,071$1,382.55$774.00ABBV
5← crossover$24,427$4,848.96$23,302$2,095.81+$1.1KCRHCF
6$36,470$10,333.24$29,150$3,237.93+$7.3KCRHCF
7$63,650$24,626.72$37,536$5,121.41+$26.1KCRHCF
8$136,713$68,607.03$50,079$8,338.38+$86.6KCRHCF
9$381,507$235,224.40$69,753$14,065.80+$311.8KCRHCF
10$1,456,017$1,047,804.46$102,337$24,771.77+$1.35MCRHCF

CRHCF vs ABBV: Complete Analysis 2026

CRHCFStock

CRH plc, through its subsidiaries, manufactures and distributes building materials. It operates in three segments: Americas Materials, Europe Materials, and Building Products. The company manufactures and supplies cement, lime, aggregates, precast, ready mixed concrete, and asphalt products; concrete masonry and hardscape products comprising pavers, blocks and kerbs, retaining walls, and related patio products; and glass and glazing products, including architectural glass, custom-engineered curtain and window walls, architectural windows, storefront systems, doors, skylights, and architectural hardware. It also offers precast concrete and polymer-based products, such as underground vaults, drainage pipes and structures, utility enclosures, and modular precast structures to the water, energy, communication, transportation, and building structures markets; and construction accessories, such as anchoring, fixing, and connection solutions, as well as lifting systems, formwork accessories, and other accessories used in construction applications. In addition, the company offers network access products, which include composite access chambers, covers, passive safety systems, retention sockets, sealants, and meter boxes; and paving and construction services. Further, it provides building and civil engineering contracting, contract surfacing, operates logistics and owned railway infrastructure; sells and distributes cement; and supplies access chambers and ducting products. It serves governments, contractors, homebuilders, homeowners, and sub-contractors. The company operates primarily in the Republic of Ireland, the United Kingdom, the rest of Europe, the United States, and internationally. CRH plc was founded in 1936 and is headquartered in Dublin, Ireland.

Full CRHCF Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this CRHCF vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CRHCF vs SCHDCRHCF vs JEPICRHCF vs OCRHCF vs KOCRHCF vs MAINCRHCF vs JNJCRHCF vs MRKCRHCF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.